Yüklüyor......

Bispecific antibodies in cancer immunotherapy

Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ther Adv Vaccines Immunother
Asıl Yazarlar: Dahlén, Eva, Veitonmäki, Niina, Norlén, Per
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2018
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5933537/
https://ncbi.nlm.nih.gov/pubmed/29998217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2515135518763280
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!